A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed by Autologous Stem Cell Transplant or DARA-VCD Consolidation and Daratumumab Maintenance in patients with Newly Diagnosed AL Amyloidosis
SWOG S2213: Study to treat patients with newly diagnosed AL Amyloidosis
Sponsor: National Cancer Institute
Enrolling: Male and Female Patients
IRB Number: AAAV1305
U.S. Govt. ID: NCT06022939
Contact: Research Nurse Navigator: 2123425162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is being done to answer the following questions: Do people with amyloid light chain (AL) amyloidosis respond better to a consolidation treatment that uses either one high dose of the drug melphalan plus stem cell transplant or more chemotherapy alone? Which treatment plan gives patients a better quality of life? To determine which treatment plan works better against AL amyloidosis, the study is set up to find out how good the treatments are at lowering the chance of AL amyloidosis causing problems in major organs of the body. The researchers will compare the results from each treatment group.
Investigator
Rajshekhar Chakraborty, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with AL amyloidosis that hasn't been treated yet, or have you received only a small amount of treatment? Yes No
Are you able to make regularly scheduled visits to the clinic for treatment and examinations? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
2123425162